SAM
PRTK

Senzar Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Senzar Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-124,519
Closed -$1.92M – 32
2016
Q4 		$1.92M Buy
124,519
+7,500
+6% +$97.4K 0.51% 29
2016
Q3 		$1.52M Sell
117,019
-17,200
-13% -$228K 0.39% 35
2016
Q2 		$1.87M Buy
+134,219
New +$1.98M 0.41% 40

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Senzar Asset Management's PRTK Position: Q1 2017 in Review

Senzar Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2017, closing a stake of 124,519 shares — an estimated $1.92M sold.

Senzar Asset Management first reported a position in PRTK in Q2 2016 and held it in 3 quarters. The position peaked at $1.92M in Q4 2016. 103 funds tracked by Wall St. Rank hold PRTK as of Q1 2017.

  • Senzar Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Senzar Asset Management sold 124,519 Paratek Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.92M.
  • Senzar Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 3 quarters.
  • Senzar Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $1.92M in Q4 2016.
  • 103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2017.

Based on Senzar Asset Management's 13F filing for Q1 2017, filed 12 May 2017.